

Date: February 12, 2026

REF: WHL/BSE/OUTCOME-07/2025-26

BSE Limited

Department of Corporate Services

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400 001.

Scrip Code:512063

Scrip Id: Wardhealth

REF: - Wardwizard Healthcare Limited (formerly known as ayoki mercantile limited)

Outcome of Meeting of Board of Directors of Wardwizard Healthcare Limited (Formerly known as Ayoki Merchantile Limited) held on Thursday, 12th February 2026.

Listing Regulation: Disclosure under Regulation 30 read with Schedule III, Reg, 33 & all other applicable Regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, ("Listing Regulations") as amended from time to time.

Dear Sir/Madam,

Pursuant to Regulation 30, 33 and schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the **Board of Directors** of the Company at its meeting held today, i.e **Thursday, 12th February, 2026**, inter alia have transacted, discussed, approved, and taken on record the following matters:

1. The Un-audited Financial Results (Standalone) of the Company for the third Quarter and Nine Month ended 31st December, 2025, of the Current Financial Year 2025-26 as recommended by the Audit Committee along with Limited Review Report of the Statutory Auditors of the Company, M/S. Mahesh Udhwani & Associates, Chartered Accountants, Vadodara, on the above un- audited financial Results.

A copy of the said Un-audited Financial Results (Standalone) containing disclosures required under Regulation 30, 33 and other provisions of the Listing Regulations as applicable along with the Limited Review Report by the Statutory Auditor of the company is enclosed.

Please note that in terms of the Company's internal Code of Conduct for Regulating, Monitoring and Reporting of Trades of Wardwizard Healthcare Limited (Formerly known as Ayoki Merchantile Limited) ('Company') read with applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended, the window for trading in Securities of the Company by the Designated Persons of the Company will open on Saturday, 15th February, 2026.

The Board meeting commenced at 04: 00P.M.(IST) and discussions on the above agenda items concluded at 05: 55 P.M. (IST).

The same will also be made available on the Company's <https://www.ayokimerchantile.com>

kindly take on record the above information.

Thanking you,

For WARDWIZARD HEALTHCARE LIMITED
(Formerly known as Ayoki Merchantile Limited)

RAJBALA KIRORIWAL
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO.: A51986

Wardwizard Healthcare Limited

CIN: L20237MH1985PLC034972 | GSTIN NO: 24AAACA4982A1Z5

Registered Office: Office no. 101, 1st Floor, Shree Sai Ashirwad CHS, Ghantali Path, Above Saibaba Mandir, Thane (West)-400602, Village-Naupada, Tehsil-Thane, Dist.-Thane, Maharashtra

Corporate Office: 11, Windward Business Park, Opp. Aadicura Hospital, Jetalpur Road, Vadodara, Gujarat-390007

Email ID: ayoki1985@gmail.com | **Website:** www.ayokimerchantile.com | **Contact Us:** +91 63591 58825



Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the WARDWIZARD HEALTHCARE LIMITED (Formerly known as Ayoki Mercantile Limited) for quarter and nine months ended December 31, 2025 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review report to


**The Board of Directors
WARDWIZARD HEALTHCARE LIMITED
(Formerly known as Ayoki Mercantile Limited)**

We have reviewed the accompanying statement of unaudited financial results of **WARDWIZARD HEALTHCARE LIMITED (Formerly known as Ayoki Mercantile Limited)** for the quarter ended 31st December, 2025 and nine month ended 31st December, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The company's Management is responsible for the preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable



accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

We draw attention to note 5 to the accompanying Statement, the company not carried out significant healthcare service activities during the quarter under review. The management is in the process of re strategizing the company's business operations and is evaluating the feasibility of future operations.

Our conclusion is not modified in respect of this matter.

For Mahesh Udhwani & Associates

Chartered Accountants

FRN :129738W

M. A. U.



Mahesh Udhwani

Partner

M.N-047328

UDIN:26047328LCZLDF8726

Place: Vadodara

Date: 12/02/2026

WARDWIZARD HEALTHCARE LIMITED

(Formerly known as Ayoki Mercantile Limited)

Corporate Identification Number (CIN): L20237MH1985PLC034972;

Registered Office: Office no. 101, 1st Floor, Shree Sai Ashirwad CHS, Ghantali Path, Above Saibaba Mandir, Thane (West) – 400602,
Village – Naupada, Tehsil – Thane, Dist. – Thane, Maharashtra

Corporate Office: 11, Windward Business Park, Opp. Aadicura Hospital, Jetalpur Road, Vadodara, Gujarat – 390 007,

Corporate Office Contact Details: +91 6359158825, Website: www.ayokimerchantile.com, Email Address: ayoki1985@gmail.com

Statement of Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025

Sr. No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		(Rupees in Lacs)	
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025	Audited
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Income from Operation							
	(a) Revenue From Operations	7.851	-	8.841	27.276	30.412	41.698	
	(b) Other Income	9.601	0.211	-	53.642	0.165	0.165	
	Total Income from Operation (a+b)	17.452	0.211	8.841	80.917	30.577	41.863	
2	EXPENSES							
	(a) Cost of materials consumed	-	-	-	-	-	-	
	(b) Purchases of Stock-in-Trade	5.577		1.973	6.456	21.960	25.338	
	(c) Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	-	-	(1.707)	15.900	(15.949)	(15.900)	
	(d) Employee benefits expense	7.478	5.914	24.969	24.122	57.791	83.783	
	(e) Finance costs	0.396	0.477	18.105	7.231	37.102	55.139	
	(f) Depreciation and amortization expense	3.687	3.091	15.502	13.998	33.966	49.466	
	(g) Other expenses	18.966	16.673	29.596	67.361	63.365	126.522	
	Total expenses (a+b+c+d+e+f+g)	36.104	26.155	88.438	135.068	198.235	324.347	
3	Profit/(loss) before exceptional items andand extraordinary items and tax (1-2)	(18.65)	(25.945)	(79.597)	(54.150)	(167.658)	(282.484)	
4	Exceptional Items	-	-	-	-	-	-	
5	Profit/(loss) before extraordinary items/Prior Period Items and tax (3-4)	(18.65)	(25.945)	(79.597)	(54.150)	(167.658)	(282.484)	
6	Extraordinary items/Prior Period Items	-	-	-	-	-	-	
7	Profit/(loss) from Ordinary activities before tax (5-6)	(18.65)	(25.945)	(79.597)	(54.150)	(167.658)	(282.484)	
8	Tax expense:							
	(1) Current tax	-	-	-	-	-	-	
	(2) Deferred tax	(0.179)	0.070	(3.487)	11.144	(7.143)	(11.158)	
	(3) Earlier Period Tax Adjustment	-	-	-	-	-	-	
9	Profit/ (Loss) for the period from continuing operations (7-8)	(18.47)	(26.014)	(76.109)	(65.294)	(160.515)	(271.326)	



M. H. Baroda

10	Other Comprehensive Income (Net of Tax)								
	A (i) Items that will not be reclassified to profit or loss	0.261	0.160	-	2.504	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
11	Total other Comprehensive Income (Net of Tax) (9+10)	(18.21)	(25.854)	(76.109)	(62.790)	(160.515)	(271.326)		
	Paid up Equity Share Capital (No of Shares) (Face Value: Rs. 10/- each)	2.450	2.450	2.450	2.450	2.450	2.450		2.450
	(Face Value: Rs. 10/- each)	10.000	10.000	10.000	10.000	10.000	10.000		10.000
	Earnings per equity share-for continuing operation):-In Rupees								
	(1) Basic	(7.54)	(10.618)	(31.065)	(26.651)	(65.517)	(110.745)		(110.745)
	(2) Diluted	(7.54)	(10.618)	(31.065)	(26.651)	(65.517)	(110.745)		(110.745)
	Earnings per equity share-for discontinued operation):-In Rupees								
	(1) Basic	-	-	-	-	-	-		-
	(2) Diluted	-	-	-	-	-	-		-
	Earnings per equity share(for discontinued & continuing operations)-In Rupees								
	(1) Basic	(7.54)	(10.618)	(31.065)	(26.651)	(65.517)	(110.745)		(110.745)
	(2) Diluted	(7.54)	(10.618)	(31.065)	(26.651)	(65.517)	(110.745)		(110.745)

Note:

- The Statement of Unaudited Financial Result for the Quarter ended Dec 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12.02.2026
- These Financial results have been prepared in accordance with the Indian Accounting Standard (Ind-AS) prescribed under Section 133 of the Company Act, 2013, read together with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The previous period figures have been regrouped/reclassified wherever required to conform to the current year's presentation.
- The Company is primarily engaged in the business of medical and health service. Company has only one reportable segment as per Ind AS 108 "Operating Segment".
- Considering the Current Scenario, the Company not carried out significant healthcare service activities during the quarter under review. The Management is in the process of re-strategizing the Company's business operations and is evaluating the feasibility of future operations.
- No investor complaints remain pending at the quarter ended on Dec 31, 2025
- The above financial results are also available on the Company's website www.ayokimerchantile.com and BSE Limited's website www.bseindia.com



FOR AND ON BEHALF OF BOARD
Wardwizard Healthcare Limited (Formerly known As Ayoki Mercantile Limited)



GAURAV GUPTA
MANAGING DIRECTOR
(DIN: 06741475)

MITTAL PATEL
CHIEF FINANCIAL OFFICER

Place: VADODARA
Date: 12/02/2026